This study reviews post study clinical endoscopy reports in follow up to patients who participated in MAY2016-07-01 with weekly erlotinib for familial adenomatous polyposis. Reviewing follow up medical records may help researchers examine the extent of rapid progression of familiar adenomatous polyposis disease burden after discontinuation of weekly erlotinib.
PRIMARY OBJECTIVE: I. To review clinical endoscopy reports, pathology reports, and other medical records related to standard-of-care endoscopic evaluations for all participants in the parent study, MAY2016-07-01, to determine the extent of reports of rapid progression of recurrent polyps after completion intervention and follow up under the parent protocol. OUTLINE: Patients who participated in MAY2016-07-01 undergo review of medical records.
Study Type
OBSERVATIONAL
Enrollment
42
Review of medical records
Mayo Clinic in Rochester
Rochester, Minnesota, United States
M D Anderson Cancer Center
Houston, Texas, United States
Number of study participants exhibiting clinically significant progression of duodenal neoplasia after completion of study drug
Will be assessed by endoscopy.
Time frame: At completion of study
Number of participants who underwent surgical resection
Will determine the number of participants who underwent surgical resection for management of advanced upper gastrointestinal (GI) neoplasia/cancer between the date of completion of intervention and 2/28/2021.
Time frame: At completion of study
Number of participants who required endoscopic resection of advanced upper gastrointestinal (GI) neoplasms
Time frame: At completion of study
Number of participants with evidence of progression of upper GI disease
Will be calculated by increase in Spigelman stage.
Time frame: At completion of study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.